Stay updated with breaking news from Exact Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The biomedical giant best known for its Cologuard at-home colon cancer screening test reported third-quarter net income of $0.8 million, or $0.00 per share, on revenue of $628 million.
Genialis, the RNA-biomarker company, today announced new data detailing how RNA sequencing data can help elucidate tumor biologies that may be amenable to immunotherapies and targeted agents. The information was presented in two posters at the...
The biomedical giant best known for its Cologuard at-home colon cancer screening test reported third-quarter net income of $0.8 million, or $0.00 per share, on revenue of $628 million.
EXAS earnings call for the period ending September 30, 2023.
/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will...